Abnormalities in HER2 signaling can result from HER2 mutations, amplification, or protein overexpression, with HER2 mutations identified in 1%–4% of NSCLC cases(Pillai et al. 2017). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.